Clinical trial · Interventional
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer
NCT00371254CI-TRIAL-00004567completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Metastasis | Breast Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dasatinib | Drug | Dasatinib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: Dasatinib
- type
- EXPERIMENTAL
- label
- 2
- interventionNames
- Drug: Dasatinib
Primary outcomes (2)
- measure
- Number of Participants With Complete Response (CR) or Partial Response (PR)
- timeFrame
- Baseline to end of study drug therapy (up to 65 weeks).
- description
- Tumor response was defined as the number of participants whose best response was CR or PR, per the Response Evaluation Criteria in Solid Tumor (RECIST): CR: disappearance of all target/non-target lesions; PR: \>= 30% decrease in the sum of the LDs of target lesions relative to the baseline sum LD.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * females, 18 or older * recurrent or progressive locally advanced, or 'triple negative' metastatic breast cancer * paraffin-embedded tissue block must be available * measurable disease * prior chemotherapy with an anthracycline, a taxane, or both (neoadjuvant, adjuvant, or metastatic setting) * 0, 1 or 2 chemotherapies in the metastatic setting * adequate organ function Exclusion Criteria: * Metastatic disease confined to bone only * Symptomatic CNS metastasis * Concurrent medical condition which may increase the risk of toxicity * Unable to take oral medication
References
Publications (0)
Data not yet available
No reference posted for this study.